The human leukocyte antigen variant that causes patients to develop antibodies to anti-tumor necrosis factor therapeutics is fairly common in patients of European and Hispanic descent, but seems not to cause immunogenicity to other biologics, according to research presented American College of Gastroenterology (ACG) 2020 clinical meeting and postgraduate course.